Epigenetic regulation of nuclear steroid receptors

Histone modifier proteins have come to the forefront in the study of gene regulation. It is now known that histone methyltransferases, acetytransferases, kinases, ubiquitinases, deacetylases and demethylases orchestrate expression of target genes by modifying both histone and non-histone proteins. The nuclear receptor (NR) superfamily govern such diverse biological processes as development, physiology and disease, including human cancer. The involvement of NR in complexes with coactivators and corepressors is necessary for regulation of target genes. This review focuses on the newly recognized interactions between the NR and histone modifying enzymes. In addition to regulating histones, the histone modifying proteins directly modify and thereby regulate NR activity. In the same manner that signaling platforms exist within the histone tails that are post-translationally processed by histone modifying proteins, cascades of post-translational modification have been identified within the NR that coordinate their activity. This review focuses on the regulation of the NR estrogen receptor (ERalpha), androgen receptor (AR) and peroxisome proliferator activated receptor-gamma (PPARgamma), given their role in tumor onset and progression.     

Development of androgen- and estrogen-responsive bioassays, members of a panel of human cell line-based highly selective steroid-responsive bioassays.

We have established highly sensitive and specific androgen and estrogen reporter cell lines which we have named AR (androgen receptor) and ERalpha (estrogen receptor alpha) CALUX (Chemically Activated LUciferase eXpression), respectively. Both bioassays are member of a panel of CALUX reporter cell lines derived from the human U2-OS osteosarcoma cell line, all using highly selective reporter constructs based with a basal promoter element linked to multimerized response elements, allowing efficient and specific measurement of compounds interfering with androgen, estrogen, progesterone, and glucocorticoid receptors. The AR CALUX bioassay contains the human androgen receptor and a luciferase reporter construct containing three androgen-responsive elements coupled to a minimal TATA promoter. This cell line was characterized by its stable expression of AR protein, its highly selective response to low levels of different natural and synthetic androgens, and its insignificant response to other nuclear hormone receptor ligands such as estrogens, progestins, and glucocorticoids. The EC50 of dihydrotestosterone (DHT) was found to be 0.13 nM, consistent with the high affinity of this ligand to the human AR. Flutamide, cyproterone acetate, and the environmental contaminants vinclozolin, DDT, methoxychlor, its metabolite HPTE, and penta-BFR showed clear antagonistic activity in the AR CALUX bioassay, competitively inhibiting DHT-mediated transactivation. The established AR CALUX bioassay proved to excel in terms of easy cell line maintenance, high fold induction range (typical 30 times over solvent control), low minimal detection limit (3.6 pM), and high androgen selectivity. Potential applications such as testing the androgenic or estrogenic activity of pure chemicals and pharmaceuticals and complex mixtures (environmental, food, feed, and clinical) are discussed.     

In vitro profiling of the endocrine disrupting potency of organochlorine pesticides

Some organochlorine pesticides (OCPs) are suspected of modulating the endocrine systems of humans. Aspects of neuro-endocrine system modulation include interactions such as agonism or antagonism of estrogen receptor (ER) binding. However, less is known about their interactions with other nuclear receptors (NRs). The objectives of this study were to determine and compare the ability of p,p'-dichlorodiphenylethane (p,p'-DDE), p,p'-dichlorodiphenyltrichloroethane (p,p'-DDT), hexachlorobenzene (HCB) and r-hexachlorocyclohexane (r-HCH) to interact with ERalpha, androgen receptor (AR), progesterone receptor (PR) and estrogen-related receptor (ERRgamma) using a set of recombined yeast strains expressing beta-galactosidase, under control of ERalpha, AR, PR or ERRgamma. The results showed that p,p'-DDE was an ERalpha agonist, AR and PR antagonist (PR>AR), while p,p'-DDT was an ERalpha agonist and AR antagonist. HCB and r-HCH were antagonists for AR and ERRgamma, while r-HCH was a PR antagonist and a weak antagonist of ERRgamma, and was able to reverse the ERRgamma inhibition induced by 4-hydroxytamoxifen. All the results suggested that, for the tested OCPs, their ability to act as endocrine disruptors involves more than one mechanism, their (anti-)agonistic effects on different receptors should not be overlooked, and the potential for additive or synergistic effects must be taken into consideration in the risk assessment process.